✦ LIBER ✦

Renal hemodynamics and pharmacokinetics of bevantolol in patients with impaired renal function

✍ Scribed by Michael Solimon; Shaul G. Massry; Vito M. Campese

Book ID: 113114167
Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 447 KB
Volume: 58
Category: Article
ISSN: 0002-9149
DOI: 10.1016/0002-9149(86)90593-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of felodipine in patien

Pharmacokinetics of felodipine in patients with impaired renal function.

✍ B. Edgar; CG Regardh; PO Attman; M. Aurell; H. Herlitz; G. Johnsson 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 1021 KB

Pharmacokinetics of carteolol in patient

Pharmacokinetics of carteolol in patients with impaired renal function

✍ M. Amemiya; K. Tabei; H. Furuya; Y. Sakairi; Y. Asano 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 503 KB

Pharmacokinetics of tenoxicam in patient

Pharmacokinetics of tenoxicam in patients with impaired renal function

✍ F. F. Horber; T. W. Guentert; E. Weidekamm; P. Heizmann; C. Descoeudres; F. J. F 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 505 KB

Clinical pharmacokinetics of bezafibrate

Clinical pharmacokinetics of bezafibrate in patients with impaired renal function

✍ P. Anderson; H. -E. Norbeck 📂 Article 📅 1981 🏛 Springer 🌐 English ⚖ 538 KB

The pharmacokinetics of ciprofloxacin in

The pharmacokinetics of ciprofloxacin in patients with impaired renal function

✍ Boelaert, J.; Valcke, Y.; Schurgers, M.; Daneels, R.; Rosseneu, M.; Rosseel, M. 📂 Article 📅 1985 🏛 Oxford University Press 🌐 English ⚖ 311 KB

Pharmacokinetics of nicorandil in patien

Pharmacokinetics of nicorandil in patients with normal and impaired renal function

✍ M. Molinaro; G. Villa; M. B. Regazzi; A. Salvadeo; S. Segagni; R. Rondanelli; E. 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 489 KB

The pharmacokinetics of oral nicorandil 20 mg 12 hourly for 9 doses was evaluated in 21 hospitalized patients with angina pectoris due to coronary heart disease and with normal and impaired renal function. Patients were divided into 3 groups based on creatinine clearance (CLCr): GROUP I (n = 6) grea